Abstract | INTRODUCTION: MATERIALS AND METHODS: C57Bl/6J mice were infused with Ang II for 14 days and either treated with the p38-MAPK inhibitor BIRB796 (50 mg/kg/day) or the vehicle as the control. We assessed vascular function in the aorta and isolated perfused kidneys. RESULTS: Chronic p38-MAPK inhibition did not alter blood pressure at the baseline, but attenuated Ang II-induced hypertension significantly (baseline: 122 ± 2 versus 119 ± 4 mmHg; Ang II: 173 ± 3 versus 155 ± 3 mmHg; p < 0.001). In addition, BIRB796 treatment improved vascular remodeling by reducing the aortic media-to-lumen ratio and decreasing the expression of the membrane metalloproteinases ( MMP) MMP-1 and MMP-9. Moreover, renal vascular dysfunction induced by chronic Ang II infusion was significantly ameliorated in the BIRP796-treated mice. Acute p38-MAPK inhibition also improved vascular function in the aorta and kidneys of Ang II-treated mice, highlighting the important role of p38-MAPK activation in the pathogenesis of vascular dysfunction. CONCLUSIONS: Our findings indicated there is an important role for p38-MAPK in regulating blood pressure and vascular injury, and highlighted its potential as a pharmaceutical target.
|
Authors | S A Potthoff, S Stamer, K Grave, E Königshausen, S H Sivritas, M Thieme, Y Mori, M Woznowski, L C Rump, J Stegbauer |
Journal | Journal of the renin-angiotensin-aldosterone system : JRAAS
(J Renin Angiotensin Aldosterone Syst)
Vol. 17
Issue 3
(Jul 2016)
ISSN: 1752-8976 [Electronic] England |
PMID | 27407119
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2016. |
Chemical References |
- Protein Kinase Inhibitors
- Angiotensin II
- S-Nitrosoglutathione
- p38 Mitogen-Activated Protein Kinases
|
Topics |
- Angiotensin II
- Animals
- Aorta
(drug effects, physiopathology)
- Blood Pressure
(drug effects)
- Hypertension
(enzymology, physiopathology)
- Kidney
(drug effects, physiopathology)
- Mice, Inbred C57BL
- Perfusion
- Protein Kinase Inhibitors
(pharmacology)
- S-Nitrosoglutathione
(pharmacology)
- Systole
(drug effects)
- Vascular Remodeling
(drug effects)
- p38 Mitogen-Activated Protein Kinases
(antagonists & inhibitors)
|